135 related articles for article (PubMed ID: 17245477)
21. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population.
Doehner W; Erdmann E; Cairns R; Clark AL; Dormandy JA; Ferrannini E; Anker SD
Int J Cardiol; 2012 Dec; 162(1):20-6. PubMed ID: 22037349
[TBL] [Abstract][Full Text] [Related]
22. [Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)].
Nitschmann S
Internist (Berl); 2007 Jan; 48(1):89-90; discussion 90-1. PubMed ID: 17187243
[No Abstract] [Full Text] [Related]
23. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
24. [Glucose-independent impact of the glitazones on the cardiovascular outcome].
Hanefeld M
MMW Fortschr Med; 2005 Jan; 147(1-2):37-9. PubMed ID: 15704569
[TBL] [Abstract][Full Text] [Related]
25. [Rediscovery of pioglitazone].
Pokoly B; Somogyi A
Orv Hetil; 2023 Jul; 164(26):1012-1019. PubMed ID: 37393546
[TBL] [Abstract][Full Text] [Related]
26. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
Nissen SE; Wolski K; Topol EJ
JAMA; 2005 Nov; 294(20):2581-6. PubMed ID: 16239637
[TBL] [Abstract][Full Text] [Related]
27. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.
Erdmann E; Harding S; Lam H; Perez A
Diabetes Obes Metab; 2016 Mar; 18(3):266-73. PubMed ID: 26592506
[TBL] [Abstract][Full Text] [Related]
28. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
DeFronzo RA; Chilton R; Norton L; Clarke G; Ryder RE; Abdul-Ghani M
Diabetes Obes Metab; 2016 May; 18(5):454-62. PubMed ID: 26919068
[TBL] [Abstract][Full Text] [Related]
29. PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Erdmann E; Dormandy J; Wilcox R; Massi-Benedetti M; Charbonnel B
Vasc Health Risk Manag; 2007; 3(4):355-70. PubMed ID: 17969365
[TBL] [Abstract][Full Text] [Related]
30. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
31. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
32. Observational follow-up of the PROactive study: a 6-year update.
Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
[TBL] [Abstract][Full Text] [Related]
33. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Veneman TF
Ned Tijdschr Geneeskd; 2006 Apr; 150(16):931-2; author reply 932-3. PubMed ID: 16686096
[No Abstract] [Full Text] [Related]
34. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Heine RJ
Ned Tijdschr Geneeskd; 2006 Apr; 150(16):930-1; author reply 932-3. PubMed ID: 16686095
[No Abstract] [Full Text] [Related]
35. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
Schneider CA; Ferrannini E; Defronzo R; Schernthaner G; Yates J; Erdmann E
J Am Soc Nephrol; 2008 Jan; 19(1):182-7. PubMed ID: 18057215
[TBL] [Abstract][Full Text] [Related]
36. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Mazzone T
Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
[TBL] [Abstract][Full Text] [Related]
37. Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?
Hiralal R; Koo KK; Gerstein HC
CMAJ; 2006 Apr; 174(8):1090-1. PubMed ID: 16606956
[No Abstract] [Full Text] [Related]
38. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials.
de Jong M; van der Worp HB; van der Graaf Y; Visseren FLJ; Westerink J
Cardiovasc Diabetol; 2017 Oct; 16(1):134. PubMed ID: 29037211
[TBL] [Abstract][Full Text] [Related]
39. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).
Erdmann E; Charbonnel B; Wilcox RG; Skene AM; Massi-Benedetti M; Yates J; Tan M; Spanheimer R; Standl E; Dormandy JA;
Diabetes Care; 2007 Nov; 30(11):2773-8. PubMed ID: 17666462
[TBL] [Abstract][Full Text] [Related]
40. Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.
Zhou Y; Huang Y; Ji X; Wang X; Shen L; Wang Y
J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 31822895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
